Abilify

DRUG3 trials

Sponsors

Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Inje University, Chengdu Kanghong Pharmaceutical Group Co., Ltd.

Conditions

BioequivalencePsychotic DisordersSchizophrenia

Phase 4

Evaluation of Effectiveness of Risperdal® Consta® Compared to Abilify® Over a Two-year Period in Patients With Schizophrenia

CompletedNCT00299702

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Psychotic Disorders, Schizophrenia

Start: 2006-02-28End: 2009-01-31Updated: 2011-12-30

The New Strategy for Pharmacological Treatment in People With Schizophrenia

Inje UniversitySchizophrenia

Start: 2006-08-31End: 2010-12-31Target: 90Updated: 2009-08-06

Unknown Phase

Bioequivalence Study of Bosiqing and ABILIFY Under Fasting/Fed Condition

Chengdu Kanghong Pharmaceutical Group Co., Ltd.Bioequivalence

Start: 2017-06-26End: 2018-06-30Target: 66Updated: 2017-07-28